Associate at Adicet Bio

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Entry Level & New Grad, Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Venture Capital, PharmaceuticalsIndustries

Requirements

MBA or equivalent advanced degree in finance, business or related fields preferred. MD or PhD is an asset, but not required
2-4 years of experience in venture capital, investment banking, or management consulting
Experience in life sciences
The ability to perform in-depth industry due diligence and data analysis
Experience working cross functionally to develop business plans and strategies
Strong track record in effectively working with senior management
Proven ability to work collaboratively internally and externally, with the ability to manage multiple stakeholders
Availability for hybrid role (2-3 days per week onsite) in Oakland, California or Cambridge, Massachusetts

Responsibilities

Propose ideas for potential investments by researching various pathways and indications, forming investment theses, and vetting those theses with Aditum Partners, Advisors, and externally curated experts
Perform research to help identify new investment opportunities, including developing and engaging with key contacts and prospects to access drug assets of interest to the Aditum Bio investment team
Participate in scientific review panels by working closely with Aditum Bio partners and scientific advisors to discuss interim findings, and using discussions and feedback to iterate on research and recommendations
Conduct due diligence on therapies of interest, including scientific, clinical, and financial aspects; work with functional Aditum Bio experts to develop clinical strategies, development plans, and budgets; present findings at Aditum Bio Investment Committee; and work with external partners on deal discussions and transactions
Help lead new company incubation and operations for licensed assets, translating clinical and scientific findings from investment generation into the new companies formed

Skills

investment analysis

due diligence

financial modeling

scientific research

clinical trials

biotech evaluation

deal negotiation

investment thesis

drug development

market research

Adicet Bio

Develops allogeneic gamma delta T cell therapies

About Adicet Bio

Adicet Bio develops cancer therapies using allogeneic gamma delta T cell therapies, which are immune cells designed to target and destroy cancer cells. Their approach utilizes donor-derived cells that are readily available, allowing for faster treatment compared to traditional methods that require a patient's own cells. The company focuses on serving healthcare providers, hospitals, and research institutions involved in cancer treatment. Adicet Bio's business model includes developing and commercializing its proprietary therapies, generating revenue through product sales and licensing agreements. A recent merger with resTORbio aims to enhance their technology and accelerate development. With significant funding, Adicet Bio is dedicated to improving cancer treatment outcomes through its unique immunotherapy approach.

Redwood City, CaliforniaHeadquarters

2014Year Founded

$141.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Risks

Increased competition could impact Adicet Bio's market share.

Potential regulatory hurdles may delay clinical trials.

Financial market volatility could affect future funding rounds.

Differentiation

Adicet Bio uses allogeneic gamma delta T cells for cancer therapy.

Their therapies are 'off-the-shelf', offering faster treatment availability.

Adicet's technology includes chimeric antigen receptors for enhanced tumor targeting.

Upsides

FDA's openness to gamma delta T cell therapies could expedite approvals.

Adicet's strong financial position supports ongoing R&D efforts.

Growing market interest in gamma delta T cell therapies indicates potential collaborations.

Land your dream remote job 3x faster with AI

Try Jobo Free